AdoRx Therapeutics, a UK based drug discovery company, and Johnson & Johnson are teaming up to develop novel therapeutics for the treatment of lung cancer. As part of the strategic collaboration, AdoRx has granted an exclusive option to research, develop and commercialize novel antagonists within the AdoRx portfolio, and the groups will collaborate on drug discovery and preclinical development activities. AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer-based on
Read More
Digital Therapeutics | Digital Health | Evidence-Based Therapeutics Interventions
Propeller Health: 84% of People with Asthma May Be Using Their Inhaler Incorrectly
The vast majority of people with asthma may be using their inhalers incorrectly, potentially making their medicine less effective and increasing their risk of asthma attacks, according to new research published in The Journal of Allergy and Clinical Immunology. Traditionally, asthma medicines require that patients take two "puffs" of their inhaler to receive the prescribed dose. Recommended Asthma Inhaler GuidelinesAsthma guidelines and patient instructions for inhaled medications recommend that
Read More
Cognoa Awarded FDA Breakthrough Designations for Diagnostic and Digital Therapeutic Devices for Autism
Cognoa, a digital health company focused on behavioral health for children, today announced FDA Breakthrough designations for it's first diagnostic and therapeutic devices to identify and treat autism. This is the foundation for its AI-based digital precision health to support the developmental and behavioral health of children, combining diagnostics and therapeutics into one platform. This signifies a big step in the company’s expansion into therapeutics.FDA Breakthrough Devices Program
Read More
Big Health Launches Digital Therapeutics App, Daylight to Improve Anxiety
Daylight is the first digital therapeutic to combine cognitive behavioral therapy, animation and the human voice to help people improve feelings of worry and anxiety. Digital therapeutics company Big Health today announced the launch of Daylight™, a scientifically rigorous yet approachable mobile app for reducing feelings of worry and anxiety. The Daylight app uses scientifically proven techniques based on cognitive behavioral therapy (CBT) to address feelings of worry and anxiety wherever and
Read More
M&A Analysis: 10 Reasons Why ResMed Acquired Propeller Health for $225M
On December 3rd, ResMed announced the acquisition of digital therapeutics maker Propeller Health for $225 million to help establish itself as a leader in COPD management across all stages of the disease. Digital medicines can help to personalize treatments, monitor patients in real-time, detect day-to-day changes in disease condition and increase patient adherence. Founded in 2010, Propeller helps people and their doctors better manage their COPD and asthma. Propeller’s digital medicine platform
Read More
ResMed to Acquire Propeller Health for $225M, Will Operate as Standalone Business
ResMed to acquire digital therapeutics maker Propeller Health for $225 million, establishing itself as a leader in COPD management.ResMed, a provider of cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has entered a definitive agreement to acquire digital therapeutics startup Propeller Health for $225M. For ResMed, the acquisition will help establish the company as a leader in COPD management across all stages of the
Read More
Force Therapeutics Raises $21M to Scale Episode-based Digital Care Delivery
Force Therapeutics, a New York-based provider of episode-based digital care delivery, today announced it has raised $21 million funding led by Insight Venture Partners. The funding will fuel Force's rapid product innovation, national expansion across major health systems, and client growth. Force is currently deployed in 60 facilities around the country and powers digital care management at leading health systems, including Geisinger, NYU Langone, Northwell Health, University Hospitals of
Read More
1DROP Raises $4.25M to Support Commercialization of Portable Medical Diagnostics Platform
1DROP, a life sciences startup developing and commercializing an easy to use laboratory quality, portable medical diagnostic testing platform has raised $4.25 million in Series A funding led by led by Christian Wildmoser (former partner CVC Capital Partners & Swiss Startup Group Investor). The round also included participation from private investors of the Swiss Startup Group including Dr. Hans-Peter Strebel (owner of On Your Marks), Beat Schillig (IFJ Institute for Young Entrepreneurs) and
Read More
WellSpan Health, Sweetch Partner to Deploy AI-Driven App for Diabetes Prevention
WellSpan Health partners with Sweetch to deploy its AI-based app to deliver large-scale prediction and prevention of diabetes to augment its employee wellness program.Diabetes is an epidemic, and our health systems are paying the price. With one in 11 adults affected globally and costs for people suffering from diabetes over 2x higher than those without the disease, it’s a pressing issue – and the latest technologies can help alleviate it.Today, integrated healthcare system WellSpan Health
Read More
Modis Therapeutics Raises $30M for Developing Medicines for Patients with Rare Genetic Diseases
Modis Therapeutics, Inc., a company developing medicines for patients with rare genetic diseases has raised $30 million in Series A funding led by F-Prime Capital Partners and OrbiMed. Joshua Grass, former F-Prime Entrepreneur-in-Residence and head of Corporate Development at BioMarin Pharmaceutical, has joined as President and Chief Executive Officer. Founding investor Aceras Life Sciences, LLC and new investor Osage University Partners also participated in the financing.Founded in 2016, Modis
Read More
